Universal influenza vaccine has successfully passed preclinical studies
The universal influenza vaccine from InvVax showed positive results in preclinical studies. At the moment, the company is preparing to conduct phase I clinical studies, at the same time attracting funding from Series A, the In-Pharma Technologist.
In preclinical studies of influenza vaccine, InvVax targeted 4 invariant regions, each of which induced an immune response in mice.
These invariant regions are vaccine components that can prevent the immune system from evading recognition and overcome viral mutations. Thus, invariant regions ensure the stability of the vaccine and have a protective effect against all strains of the virus without the threat of mutation or resistance of the virus.
Data DKI were obtained by intranasal or subcutaneous administration of the candidate vaccine in mice.
The proportion of survivors in the group of mice that received the vaccine was 100%, whereas in the control group that did not receive the vaccine, this figure was 0%.
According to Arthur Young (Founder and President of InvVax): “We are hoping for a vaccine to be purchased by one of the Big Pharma representatives after the end of the Phase I clinical studies, approximately 2021-2023 We also expect approval of a new experimental drug around 2021.”
Link: pharmvestnik.ru